THE ASSOCIATION OF TRAINEE INVOLVEMENT IN RADICAL CYSTECTOMY WITH PERIOPERATIVE AND ONCOLOGIC OUTCOMES

Urology ◽  
2022 ◽  
Author(s):  
Matvey Tsivian ◽  
Raevti Bole ◽  
Vignesh T Packiam ◽  
Stephen A Boorjian ◽  
Prabin Thapa ◽  
...  
2018 ◽  
Vol 17 (8) ◽  
pp. 225-226
Author(s):  
F. Chessa ◽  
A. Möller ◽  
R. Schiavina ◽  
M. Borghesi ◽  
O. Laurin ◽  
...  

2020 ◽  
Vol 38 (3) ◽  
pp. 76.e1-76.e9 ◽  
Author(s):  
Giuseppe Rosiello ◽  
Carlotta Palumbo ◽  
Sophie Knipper ◽  
Angela Pecoraro ◽  
Cristina Dzyuba-Negrean ◽  
...  

2019 ◽  
Vol 17 (5) ◽  
pp. e1048-e1053 ◽  
Author(s):  
Shiqiang Su ◽  
Liangyou Gu ◽  
Xin Ma ◽  
Hongzhao Li ◽  
Baojun Wang ◽  
...  

2013 ◽  
Vol 64 (2) ◽  
pp. 227
Author(s):  
Oussama Elhage ◽  
Muhammad Shamim Khan ◽  
Prokar Dasgupta

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 290-290
Author(s):  
C. Mmeje ◽  
R. Nunez-Nateras ◽  
R. Pruthi ◽  
M. E. Nielsen ◽  
E. Wallen ◽  
...  

290 Background: Previous studies have shown robot assisted radical cystectomy (RARC) to have equivalent perioperative outcomes to open radical cystectomy. There are few reports that have examined the oncologic results of RARC specifically with respect to node-positive patients. We report the outcomes of node-positive patients who have undergone RARC with medium-term (at least 1 year) follow-up. Methods: A total of 275 patients underwent RARC at two institutions for invasive bladder cancer between 2005-present. We examined the 50 patients with node-positive disease that had a minimum of one year follow-up. Oncologic outcomes, recurrence free survival (RFS), and disease specific survival (DSS) were analyzed and compared to the open literature. Results: Mean clinical follow up in this case series was 29 months (range 12–64 months). The mean number of lymph nodes removed was 18 (range 5–35), and mean number of positive LNs was 3.1 (range 1–12). Overall rate of LN positivity was 26%. Mean LN density was 18%. Seventeen (34%) patients had ≤ pT2 disease and 33 (66%) pT3/T4 disease. At this follow-up, 29 patients have recurred, 21 patients died of disease, giving a RFS and DSS of 42% and 58%, respectively. Mean (median) time to recurrence was 10.2 months (9 months). A total of 60% of patients received peri-operative chemotherapy in this cohort. These findings are consistent with prior reports of such oncologic outcomes in node-positive patients in open series. Conclusions: The oncologic follow-up of patients undergoing RARC with LN positive disease appears to have acceptable outcomes during medium term (mean 29 months) follow-up. As our follow-up increases, we expect to continue to accurately define the long-term clinical suitability and oncologic success of this procedure in this high-risk population. No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document